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Screening for breast cancer is now routinely performed in
most countries where the disease is common. The benefits of
screening have been established and are generally accepted.
However, screening does have the potential for harm, the
most important aspects of which are overdiagnosis and
overtreatment. Breast Cancer Research has invited a series
of papers to address the component dimensions of the field,
and in particular to estimate the extent to which it occurs. The
first article in the series, in which Sue Moss reviews
overdiagnosis in randomised controlled trials of breast cancer
screening, is published in this issue [1].
Screening for cancer is based on the supposition that earlier
diagnosis will lead to improved prognosis. Experience of
screening for several types of cancer (breast, cervix uteri or
large bowel) has shown that on average this will be true, in
the sense that groups targeted for screening for these
cancers show reduced cancer-specific mortality. However,
what is true on average may conceal major differences
between individuals. For most cancer types there is a wide
divergence of behaviour between individual cancers. Some,
usually the most malignant, will be fast growing and less
amenable to the benefits of earlier detection, particularly in
the context of periodic testing in a mass screening
programme; others, often the more benign, will be slow
growing and probably successfully treatable whenever
diagnosed. Among these slower-growing tumours will be a
proportion that were never destined to surface as clinically
apparent cancers in the lifetime of the individual. The effect of
this heterogeneity has been seen particularly clearly in the
early randomised trials of screening for lung cancer, in which
despite an increase in the number of early (stage 1) cancers
diagnosed on the screened arm of the trial, no reduction in
lung cancer mortality rates was seen among those
randomised to screening. That is, the cancers preferentially
detected at screening were not those that prove fatal.
Furthermore, many more early cancers were diagnosed
through screening than appeared on the control arm even
after extended follow-up. In these trials, screening yielded no
benefit but generated considerable harm.
Lesions that are detected at screening but which would not
have surfaced clinically in the lifetime of the individual
constitute overdiagnosis, the major form of harm associated
with screening programmes. The individuals concerned
undergo unnecessary further investigations and treatment,
with all the consequent side effects, and the health care
system has to bear the unnecessary costs. Overdiagnosis
arises because histopathology, the current basis for the
diagnosis of malignancy, is not a precise predictor of
outcome. If tests were available that could accurately predict
behaviour – and the identification of such tests should be a
high priority in screening research – then the problems
associated with overdiagnosis would largely disappear. In the
absence of such tests, however, overdiagnosis must form an
important component of any cost–benefit assessment. The
two factors that need ascertaining are, first, the extent of the
problem – in a screening programme, how many lesions will
be detected and treated that would never have progressed –
and, second, the harm caused to an individual who receives
such a diagnosis. Estimating the extent of overdiagnosis
presents particular problems. Because, in the usual situation,
detected lesions are treated, it will be impossible to tell for
any specific individual whether a detected lesion represents
overdiagnosis. Any approach to estimating the extent of
overdiagnosis in a screening programme must be indirect
and must be based on the performance of the programme as
a whole.
The first attempt to investigate the extent of overdiagnosis
was with cervical cytology screening, in which the large
discrepancy between the number of lesions treated, almost
all of which were pre-invasive, and the number of cancers that
might have occurred in the absence of screening was
referred to as the ‘yawning gap’. Its identification was used
initially in an attempt to discredit cervical screening but was
Editorial
Overdiagnosis and breast cancer screening
Nick E Day
The Institute of Public Health, University of Cambridge, Cambridge, UK
Corresponding author: Nick E Day, nick.day@srl.cam.ac.uk 
Published: 30 August 2005 Breast Cancer Research 2005, 7:228-229 (DOI 10.1186/bcr1321)
This article is online at http://breast-cancer-research.com/content/7/5/228
© 2005 BioMed Central Ltd
See related review by Moss in this issue [http://breast-cancer-research.com/content/7/5/230]229
Available online http://breast-cancer-research.com/content/7/5/228
later recognised as simply a component, albeit important, of
the overall cost–benefit balance. The degree of such
overdiagnosis has been reviewed in the recent IARC
Handbook on Cervix Cancer Screening [2]. With cervical
cancer screening, overdiagnosis occurs at the pre-invasive
stage, when the lesions are relatively easily treated. Prostate
cancer screening provides a striking contrast: most
preclinical lesions detected by testing for prostate-specific
antigen are early invasive cancers, the treatment of which
often has major and long-lasting side effects. It has been
known for many years that many more men harbour
histologically malignant tumours than will ever develop, or die
from, clinical prostatic cancer, so that the question of
overdiagnosis by screening becomes a major issue, of
sufficient importance to inhibit the widespead adoption of
such screening. An attempt to estimate the degree of
overdiagnosis has been made within the European trial of
prostate cancer screening, taking a modelling approach. The
results suggest that about 50% of histologically diagnosed
cancers arising in a screening programme might not have
progressed to clinical cancers within the lifetime of the
individual [3,4].
In breast cancer screening, the issue of overdiagnosis is
presented descriptively in the IARC Handbook on Breast
Cancer Screening [5]. This series of papers examines in
greater depth a range of issues associated with screening-
associated overdiagnosis, including a general discussion
from both a biological and epidemiological perspective.
Randomised trials of screening provide the clearest evidence
from which to estimate the extent of overdiagnosis. A range
of approaches are described, including the micro-simulation
modelling developed in The Netherlands and used to great
effect for prostate cancer screening. However, randomised
trials often represent the effect of screening performed under
optimum conditions: they indicate what can be achieved. In
contrast, in public health terms, what is important is the result
of screening when applied on a routine basis. Estimating the
extent of overdiagnosis in these circumstances poses
separate problems, and the issue is given specific attention.
To complement these synoptic, population-based approaches,
attention is also given to the process of overdiagnosis itself.
Histologically, what seem to be the tumour characteristics
that are associated with overdiagnosis? What is the role of
ductal carcinoma in situ in breast cancer screening, what are
the probabilities of progression to invasion over time? Rates
of detection of ductal carcinoma in situ vary widely between
screening programmes; what are the implications for the
overall net benefit that the programme yields? Breast cancer
screening is a multiphase process, the initial components of
which are radiological. To what extent is overdiagnosis an
issue for radiologists?
Breast screening is now established in many countries. The
issues of current importance are not those referring to
whether there is a net benefit, but how screening can be
undertaken to optimise the net benefit. A crucial component
of this is to understand the phenomenon of overdiagnosis,
both quantitatively and qualitatively, so that the associated
harm can be minimised. A secondary issue is the question of
overtreatment of cancers that would progress but are
diagnosed at a very early stage. It is hoped that publication of
this series will contribute to clarification of these issues for
the improvement of breast screening programmes.
Competing interests
The author(s) declare that they have no competing interests.
References
1. Moss S: Overdiagnosis and overtreatment of breast cancer:
Overdiagnosis in randomised controlled trials of breast
cancer screening. Breast Cancer Res 2005, 7:230-234.
2. International Agency for Research on Cancer: IARC Handbooks
of Cancer Prevention. Cervix Cancer Screening. Lyon: IARC
Press; 2005.
3. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RAM,
Schroder FH, de Koning HJ: Lead times and overdetection due
to prostate-specific antigen screening: estimates from the
European Randomized Study of Screening for Prostate
Cancer. J Natl Cancer Inst 2003, 95:868-877.
4. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann
PH, Feuer EJ: Overdiagnosis due to prostate-specific antigen
screening: lessons from U.S. prostate cancer incidence
trends. J Natl Cancer Inst 2002, 94:981-90.
5. International Agency for Research on Cancer: IARC Handbooks
of Cancer Prevention. Breast Cancer Screening. Lyon: IARC
Press; 2002.